ABSTRACT: Letrozole (Femara) is a nonsteroidal aromatase inhibitor that is approximately 10,000 times as potent as aminoglutethimide in vivo. Two pivotal multinational phase III trials have compared letrozole (0.5 and 2.5 mg/d) against megestrol acetate and aminoglutethimide, respectively, in patients with locally advanced or metastatic breast cancer. The letrozole vs megestrol acetate trial showed the superiority of letrozole (2.5 mg/d) over megestrol acetate with respect to response rate, response duration, duration of overall clinical benefit (complete response plus partial response plus stable disease ³ 6 months), time to progression, and time to treatment failure. The letrozole-treated patients also showed a nonsignificant trend toward better survival. In the letrozole vs aminoglutethimide trial, letrozole (2.5 mg/d) was significantly superior in terms of duration of overall clinical benefit and survival. There were also strong trends favoring letrozole with regard to objective response rate and duration of response. Unexpectedly, both trials demonstrated a dose-response effect for 2.5 mg of letrozole over 0.5 mg in terms of response and overall survival. This finding raises the possibility that intratumoral aromatase suppression may be more relevant in breast cancer therapy than are plasma estrogen levels.[ONCOLOGY(Suppl 5):41-44, 1998]
Over the last 15 years, inhibitors of aromatase, the enzyme responsible for estrogen biosynthesis, have been found to be active agents in the treatment of breast cancer. Aminoglutethimide, the first aromatase inhibitor, was shown to be an effective, useful agent, with activity at least equivalent to that of tamoxifen (Nolvadex) in advanced breast cancer. Aminoglutethimide was associated with unwanted side effects, however, including somnolence (at higher doses) and rash.
The next step in the clinical development of aromatase inhibitors was 4-hydroxyandrostenedione (formestane), the first steroidal compound to be structurally designed to inhibit aromatase. This agent proved to be more specific than aminoglutethimide and had fewer systemic side effects, but it had poor oral availability and therefore had to be given by intravenous injection.
A third generation of nonsteroidal imidazole aromatase inhibitors has now been developed; these new inhibitors are several orders more potent than aminoglutethimide. The first of the third-generation agents, fadrozole (COS 16949A), initially led the field in clinical trials. It gradually became apparent, however, that fadrozole had minor but unwanted aldosterone-suppressing effects.
Three other important imidazole-type aromatase inhibitors are now in advanced clinical trials or are registered for use in advanced breast cancer: anastrozole (Arimidex), vorozole (Rivizor), and letrozole (Femara). This paper focuses on the clinical development of letrozole, with particular emphasis on the pivotal large phase III clinical trials that led to its approval by the FDA for use in the treatment of advanced breast cancer.
Letrozole is a nonsteroidal triazole derivative. One of the most potent aromatase inhibitors yet developed, letrozole is approximately 10,000 times as potent as aminoglutethimide in vivo, with no evidence of inhibition of other steroid pathways at doses required to inhibit estrogen. In animal models, it achieves almost complete regression of estrogen-dependent, dimethylbenzanthracene-induced mammary tumors.
In a phase I study conducted at the Royal Marsden Hospital, 21 postmenopausal patients were treated with letrozole in three successive groups of seven, receiving 0.1, 0.5, and 2.5 mg/d orally, respectively. Letrozole produced a statistically significant suppression of estradiol by 74% from baseline levels and estrone by 79% (P < .0001). Suppression occurred in all three patient groups, with many patients having serum estradiol and estrone concentrations below the limit of detection of the assays (3 and 10 pM, respectively), corresponding to a maximum measurable estrogen suppression of 86%. Letrozole had no significant effect on serum follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), cortisol, 17-hydroxyprogesterone, androstenedione, or aldosterone.
In a subsequent Royal Marsden phase I trial of letrozole specifically designed to measure aromatase inhibition in vivo (see below), 13 patients were randomly allocated to 0.5 and 2.5 mg/d. Estrone and estradiol levels fell by 82% and 84.1%, respectively, at 0.5 mg/d and by 81% and 68%, respectively, at 2.5 mg/d.
In a nonrandomized comparative phase I clinical efficacy study, Demers et al compared the endocrine-suppressing effects of fadrozole and letrozole using the same high-sensitivity estrogen radioimmunoassay. Letrozole appeared to be the more potent of the two drugs. Fadrozole achieved a 68% suppression of estrone and 70% suppression of estradiol at all of the doses used. Letrozole, at doses of 0.1 to 5 mg/d, suppressed both estrone and estradiol by > 95%, resulting in undetectable levels in many patients.
At the Royal Marsden, we measured in vivo aromatase inhibition by letrozole in 13 postmenopausal patients with advanced breast cancer randomized to a daily dose of 0.5 or 2.5 mg for at least 6 weeks. After 6 weeks, 0.5 and 2.5 mg/d of letrozole inhibited aromatization by a mean (geometric) of 98.4% (range, 97.3% to > 99.1%) and > 98.9% (98.5% to > 99.1%), respectively. This was a greater degree of aromatase inhibition than had been achieved previously with any other inhibitor.
In our original phase I study, 7 (33%) of 21 patients achieved an objective response and 5 had stable disease for more than 3 months. All of these patients had received at least one prior endocrine treatment.
In an American phase I trial, 23 heavily pretreated postmenopausal patients with metastatic breast cancer were given letrozole at doses ranging from 0.1 to 5 mg/d. Only two patients (10%) had partial responses, but an additional seven had stable disease.
Better results were achieved in a third phase I Italian trial, in which 14 postmenopausal patients were treated with 0.5 mg/d of letrozole. One patient achieved a complete response and four patients, a partial response, for an overall objective response rate of 36%. No toxic effects relating to letrozole were seen in any patient.
1. Smith IE, Fitzharris BM, McKinna JA, et al: Aminoglutethimide in the treatment of metastatic breast carcinoma. Lancet 2:646-649, 1978.
2. Smith IE, Harris AL, Morgan M, et al: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial. Br Med J Clin Res Ed 283:1432-1434, 1981.
3. Stuart Harris R, Dowsett M, Bozek T, et al: Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet 2:604-607, 1984.
4. Brodie AM, Garrett WM, Hendrickson JR, et al: Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3, 17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 38:693-702, 1981.
5. Coombes RC, Hughes SW, Dowsett M: 4-hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer. Eur J Cancer 28a:1941-1945, 1992.
6. Bhatnagar AS, Hausler A, Schieweck K: Inhibition of aromatase in vitro and in vivo by aromatase inhibitors. J Enzyme Inhib 4:179-186, 1990.
7. Iveson TJ, Smith IE, Ahern J, et al: Phase l study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 53:266-270, 1993.
8. Dowsett M, Jones A, Johnston SRD, et al: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1:1511-1515, 1995.
9. Demers LM: Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 30:95-102, 1994.
10. Lipton A, Demers LM, Harvey HA, et al: Letrozole (CGS 20267): A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 75:2132-2138, 1995.
11. Bisagni G, Cocconi G, Scaglione F, et al: Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer: A pilot study. Ann Oncol 7:99-102, 1996.
12. Dombernowsky P, Smith I, Falkson G, et al: Letrozole (Femara), a new oral aromatase inhibitor for advanced breast cancer. Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998.
13. Marty M, Gershanovich M, Campos B, et al: Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens (abstract). Proc Am Soc Clin Oncol 16:156a, 1997.